Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

FTH earnings analysis

Filed August 4, 2026 · Our reading of the company's report

The latest report

Faeth remains a pre-revenue clinical-stage biotechnology company, so revenue, gross margin, operating margin, segment revenue and reported EPS were not disclosed in the provided filing text. Q2 net loss expanded by…

Read full summary

Faeth remains a pre-revenue clinical-stage biotechnology company, so revenue, gross margin, operating margin, segment revenue and reported EPS were not disclosed in the provided filing text. Q2 net loss expanded by $11.071 million year over year to $16.007 million as PIKTOR development and post-acquisition personnel, consulting and administrative costs lifted operating expenses to $18.385 million from $5.206 million. Liquidity of $186.4 million provides stated runway through both principal clinical readouts, but operating cash consumption rose to $26.406 million in the first half and the recent approval of a competing multi-node inhibitor increases clinical and commercial execution risk.

Read the original on SEC.gov

What stood out

  • $186.4M liquidity supports clinical readouts

    Cash, cash equivalents and marketable securities totaled $186.4 million at June 30, 2026, including $183.1 million of net proceeds from the 2026 private placement. Management believes this liquidity funds operations through readouts from both ongoing PIKTOR studies.

  • Interest income increased by $2.1M

    Other income rose to $2.4 million in Q2 2026 from $0.3 million in Q2 2025, primarily from higher interest income on securities.

  • Two PIKTOR clinical catalysts approaching

    The lead PIKTOR program is in a Phase 2 endometrial-cancer study with topline data anticipated by year-end, while the Phase 1b/2 HR+/HER2- breast-cancer study dosed its first patient in April 2026 and has interim data expected in 2027.

What to watch

  • Loss and operating-cost base expanded sharply

    Q2 net loss widened to $16.007 million from $4.936 million a year earlier as R&D increased to $9.180 million from $2.533 million and G&A rose to $9.205 million from $2.673 million. The six-month loss was $186.243 million, including a $132.957 million acquired-I​​PR&D charge.

  • Cash burn more than doubled year over year

    Operating cash use increased to $26.406 million in the first six months of 2026 from $13.003 million in the prior-year period. Management expects ongoing R&D to increase significantly as PIKTOR advances, despite lower future acquisition-related nonrecurring costs.

  • Approved competitor may raise PIKTOR hurdle

    A newly emphasized competitive risk is that the FDA approved competitor gedatolisib in July 2026 for HR+/HER2-, PIK3CA wild-type metastatic breast cancer; PIKTOR's breast-cancer trial only began in April 2026 and interim data is not expected until 2027. Management says an established multi-node-inhibitor standard of care could require larger, longer, and more expensive PIKTOR trials.

Management's outlook

No numerical revenue or EPS guidance was provided. Management expects cash, cash equivalents and marketable securities of $186.4 million to fund operations through topline readouts from both PIKTOR studies; FTH-PIK-201 topline data is anticipated by year-end and FTH-PIK-101 interim data is expected in 2027.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.